Exploring biomarkers to predict tumor response to radiotherapy
Exploration of Potential Biomarkers to Predict Tumor Response to Radiotherapy in Patients With Solid Tumors
This study is trying to find markers in tumors and blood that can help predict how well solid tumors will respond to radiotherapy in patients who need this treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Sex | All |
| Sponsor | Shantou University Medical College Academic / other |
| Drugs / interventions | immunotherapy, radiation |
| Locations | 1 site (Shantou, Guangdong) |
| Trial ID | NCT03744819 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify potential biomarkers that can predict how solid tumors respond to radiotherapy. Patients with pathologically confirmed solid tumors requiring radiotherapy or surgery will be recruited, and tumor samples will be collected to establish baseline biomarker status. Additionally, blood samples and microbiota will be collected before and after surgery, as well as during the course of radiotherapy for those patients. The biological specimens will be analyzed to assess tumor phenotypes and explore biomarkers that could indicate therapeutic outcomes and prognosis.
Who should consider this trial
Good fit: Ideal candidates include patients with pathologically confirmed solid tumors who are scheduled for radiotherapy or surgery and can provide informed consent.
Not a fit: Patients with a history of autoimmune diseases, prior immunotherapy, or contraindications for biopsy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment plans for patients with solid tumors, improving their therapeutic outcomes.
How similar studies have performed: While the exploration of biomarkers in relation to tumor response is a growing field, this specific approach may offer novel insights into solid tumors and their treatment responses.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathological proven diagnosis of solid tumors * Tumor accessible for biopsy during the course of radiotherapy or tumor samples could be obtained via surgery * Patient must provide study-specific informed consent prior to study entry Exclusion Criteria: * History of autoimmune diseases * History of immunotherapy * Prior radiation therapy that would result in overlap of planned radiation therapy fields * Will receive immunotherapy during the course of radiotherapy * Contraindications for biopsy, such as high bleeding risk
Where this trial is running
Shantou, Guangdong
- Cancer Hospital, Shantou University Medical College — Shantou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Chuangzhen Chen, MD — Affiliated Cancer Hospital of Shantou University Medical College
- Study coordinator: Chuangzhen Chen, MD
- Email: stccz@139.com
- Phone: +86 13923995569
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.